Stay updated on Volitinib for Primary CNS Tumors Clinical Trial
Sign up to get notified when there's something new on the Volitinib for Primary CNS Tumors Clinical Trial page.

Latest updates to the Volitinib for Primary CNS Tumors Clinical Trial page
- Check3 days agoChange DetectedA new Phase I Savolitinib study title is added, expanding the scope to MET-activated CNS tumors and listing related drug names (Orpathys, HMPL504, AZD-6094). Minor eligibility wording changes (serum creatinine) and procedural updates (e.g., Sample Collection) are also reflected.SummaryDifference0.6%

- Check11 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating a new build. The previous revision tag was removed.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page revision indicator was updated from v3.6.2 to v3.6.3, signaling an update to the page template or platform components.SummaryDifference0.0%

- Check39 days agoChange DetectedSavolitinib study results have been posted and the study details have been updated. The Volitinib entry was removed, refocusing the page on the Savolitinib trial.SummaryDifference4%

- Check53 days agoChange DetectedThe page now indicates the study is no longer recruiting participants. New help sections (How to Read a Study Record, Common Questions, How to Join a Study) were added, and the Intervention/Treatment label was standardized with a revision note (v3.6.0).SummaryDifference0.4%

- Check60 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous v3.5.4, indicating a small update to the page's revision history.SummaryDifference0.0%

Stay in the know with updates to Volitinib for Primary CNS Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Volitinib for Primary CNS Tumors Clinical Trial page.